NCE Discovery and Domainex Merge to Create a new Drug Discovery Company
News Jul 11, 2007
Domainex Ltd and NCE Discovery Ltd merged to form a new drug discovery company focused on nucleotide triphosphate (NTP)-dependent proteins. The parent company will be known as Domainex, and it will offer access to its technology platform on a 'fee for service' basis through its service division, which will trade as NCE Discovery.
The new company combines NCED’s expertise in medicinal chemistry with Domainex’s innovative Combinatorial Domain Hunting (CDH) technique for producing recombinant proteins, forming a well-rounded platform for drug discovery.
Domainex will apply this combination of structural biology and medicinal chemistry approaches to the development of small-molecule drugs with activity against key NTP-dependent protein targets.
Both NCE Discovery and Domainex are spinout companies from University College London (UCL) which, via UCL Cruciform Ltd, is a major shareholder of NCE Discovery and holds shares directly in Domainex. Domainex is also a spinout of the Institute of Cancer Research and Birkbeck College London. UCL Business plc (UCLB), a wholly owned subsidiary of UCL, has also become an investor in the new merged company.
“We are delighted to launch a drug-focused platform technology company with novel approaches to both biology and chemistry,” said Dr Keith Powell, CEO of Domainex.
Alan Stuttle, an assistant director of UCLB, commented: “Working alongside the Bloomsbury BioSeed Fund, UCLB sees this resultant merger as an opportunity to invest in the strong combination that these two companies have now become, potentially delivering a much greater presence in the marketplace.”
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018